tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
AstraZeneca sees FY26 core EPS up low double-digit percentage
PremiumThe FlyAstraZeneca sees FY26 core EPS up low double-digit percentage
8d ago
AstraZeneca reports Q4 core EPS $2.12 vs. $2.09 last year
Premium
The Fly
AstraZeneca reports Q4 core EPS $2.12 vs. $2.09 last year
8d ago
AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside
Premium
Ratings
AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside
8d ago
AstraZeneca price target raised to 11,500 GBp from 11,000 GBp at Deutsche Bank
PremiumThe FlyAstraZeneca price target raised to 11,500 GBp from 11,000 GBp at Deutsche Bank
12d ago
AstraZeneca’s TAPER Study Targets Simpler Severe Asthma Care With Tezepelumab
Premium
Company Announcements
AstraZeneca’s TAPER Study Targets Simpler Severe Asthma Care With Tezepelumab
12d ago
AstraZeneca’s Ondexxya Real-World Bleeding Study Update: What Investors Should Watch
Premium
Company Announcements
AstraZeneca’s Ondexxya Real-World Bleeding Study Update: What Investors Should Watch
12d ago
AstraZeneca rises 101.5%
PremiumThe FlyAstraZeneca rises 101.5%
15d ago
AstraZeneca’s AZD4063 Edges Forward in Rare Genetic Cardiomyopathy Trial: What Investors Should Watch
Premium
Company Announcements
AstraZeneca’s AZD4063 Edges Forward in Rare Genetic Cardiomyopathy Trial: What Investors Should Watch
15d ago
AstraZeneca Completes Key Drug–Interaction Study for AZD5004, Nudging Pipeline Risk Lower
Premium
Company Announcements
AstraZeneca Completes Key Drug–Interaction Study for AZD5004, Nudging Pipeline Risk Lower
15d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100